Cell Therapeutics, Inc. (“CTI”) (Nasdaq and MTA: CTIC) announced that the U.S. Food and Drug Administration’s (“FDA”) Oncologic Drugs Advisory Committee (“ODAC”) will review CTI’s New Drug Application (“NDA”) for pixantrone for the treatment of relapsed/refractory aggressive non-Hodgkin’s lymphoma (“NHL”) on March 22, 2010. The meeting was to take place on February 10, 2010, but the FDA postponed the meeting because of severe weather conditions in the Washington, D.C. area… (Source: Health News from Medical News Today)

Further information:

Article source

Related posts:

1. Exenatide Once Weekly New Drug Application Review Extended By FDA Due To Weather-Related Closure
2. Cell Therapeutics: FDA Approves Italian Factory
3. Jazz Pharmaceuticals Announces FDA Acceptance Of Its New Drug Application For JZP-6 (sodium Oxybate) For The Treatment Of Fibromyalgia
4. Cellceutix Completes Successful Pre-IND Meeting With FDA For Cancer Drug
5. Forest Laboratories Receives Decision From FDA For Supplemental New Drug Application For Bystolic(R)